Clinical Results of Neurodegenerative Study

AFFiRiS Announces Results of a Phase I Clinical Study Using AFFITOPEs® PD01A and PD03A, Confirming Safety and Tolerability for Both Compounds as well as Immunogenicity for PD01A in Early MSA patients AFFITOPEs® PD01A and PD03A Safe and Well Tolerated: Primary Endpoint of Phase I Study Met Immune Response against AFFITOPE® PD01A and Alpha-Synuclein Seen in […]